15 нояб. 2023 г. · This guideline gives recommendations on CV risk stratification as well as on screening, diagnosis, and treatment of CVD in patients with ...

25 авг. 2023 г. · As such, in patients with diabetes and ASCVD, treatment with GLP-1 RAs and/or SGLT2 inhibitors is recommended to reduce CV risk, independent of ... Management of coronary... · Type 1 diabetes and...

14 окт. 2023 г. · 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-4140.

28 авг. 2023 г. · The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use ...

29 авг. 2023 г. · The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use ...

6 дек. 2023 г. · The new 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes focus on risk assessment and treatment of ...

14 февр. 2024 г. · In patients with ASCVD and T2DM, it is recommended to treat with a GLP-1 RA and an SGLT2 inhibitor with proven benefit to reduce CV risk.

25 авг. 2023 г. · Based on the ESC Guidelines, all patients with diabetes should be checked for the symptoms or signs of atherosclerotic cardiovascular disease, ...

The new guidelines of the European Society of Cardiology (ESC) were published in 2023 and provide clear recommendations for the management of cardiovascular ...

11 сент. 2023 г. · The following are key points to remember from the 2023 European Society of Cardiology (ESC) guidelines for the management of cardiovascular disease (CVD) in ...